person
Emilio B.
- Country
- Italy
- Department
- Oncologia Medica
Research Overview
assignment
64
Clinical Trials ·
- A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination with Atezolizumab Compared with Placebo in Combination with Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
- Evaluation of Pembrolizumab, Patritumab Deruxtecan, and Drug Combinations in Stage IV Non-Small Cell Lung Cancer: A Phase 2 Umbrella Study
- Phase 2 Study of V940 in Combination with Pembrolizumab and Combination Therapy for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer
Data & Insights
medical_services
Primary Speciality
Main therapeutic area
handshake
Return Partnerships
Recurring site collaborations
465
Sites with multiple studies
Has run more than one trial at 465 of 739 partner sites.
Specializations
Non-Small Cell Lung Cancer Expertise
This investigator specializes in conducting research on various stages and types of non-small cell lung cancer (NSCLC), with particular focus on resectable tumors and advanced metastatic disease.
- HER2-mutated NSCLC
- PD-L1 expressing tumors
- ROS1-positive lung cancer
- ALK-positive NSCLC
Breast Cancer Research
The investigator conducts studies in hormone receptor-positive breast cancer, focusing on early-stage disease and novel therapeutic approaches.
- ER-positive/HER2-negative breast cancer
- Neoadjuvant therapy approaches
- Hormone therapy optimization
Therapeutic Approaches
The investigator explores various therapeutic strategies including immunotherapy combinations and targeted therapies.
- Chemoradiation therapy
- Neoadjuvant treatment
- Maintenance therapy
- Combination immunotherapy
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.